Headache, I agree that it is not entirely clear, but I understand it as they used the colorimetric assay for the detection of stage 1 and cancers, as mentioned in the previous PR. This means that they are finished with the development of the assay and that it works. Sure we will likely see PR’s relating to stage 1 and 2 in prostate, lung, colon/rectal etc., , but I see it as great news. It also means that they are closer to develop rapid test.
“The improvements resulting from this work have magnified the measured differences in serum values for RECAF between normal and cancer patients. This large difference between cancers and normal patients not only allows the detection of smaller tumors, (as recently shown for breast cancers where we can now detect 90% of early stages I and II); “
Perhaps the most important part is that they have just shown to us that it is feasible to produce a color based assay and thus to integrate the technology into automated systems. IOW, the probability for a successful completed feasibility review with Abbott has just risen dramatically.
Another very import thing to extract from this PR is that should they now succeed in making license agreements with other large pharma’s we don’t have to go through a year (like in the case of Abbott) waiting for them create a color based assay that can be integrated into their automated systems. Ie, time to commercialization is now much shorter both for the licensee and of course for us.
Secondly they might be able to get much larger up front payments and perhaps even larger royalties as the technology has been developed one step further and now also show detection of the important early stages of cancer.
Thirdly it means that they can now ship the test to a much higher degree to other independent universities and scientists for third party verification. Something that Bocxman has asked for repeatedly.
Also, don’t forget that we don’t necessarily need other licensees to become successful, as we still have Abbott.
I see a lot of positive info
AI
